Statistics and outlook for non Hodgkin lymphoma
This page is about statistics and what they can tell us about the outlook for people with non Hodgkin lymphoma. You can find the following information
Statistics and outlook for non Hodgkin lymphoma
Outlook means your chances of getting better. Your doctor may call this your prognosis. The likely outcome of non Hodgkin lymphoma depends partly on how advanced the cancer is when it is diagnosed (the stage). But the type of lymphoma and whether your lymphoma is low grade (indolent) or high grade (aggressive) is also very important.
The statistics we use are taken from a variety of sources, including the opinions and experience of the experts who check every section of Cancer Research UK's patient information. They are intended as a general guide only. For the more complete picture in your case, you’d have to speak to your own specialist.
The information further down the page is quite detailed. We include statistics because people ask for them, but not everyone wants to read this type of information. Remember that you can skip this page if you don't want to read it. You can always come back to it.
How reliable are cancer statistics?
No statistics can tell you what will happen to you. Your cancer is unique. Many individual factors affect your treatment and your outlook. Outcomes for patients with most types of lymphoma have improved steadily over time. Because of the way they are collected statistics tend to show these improvements some years later.
You can view and print the quick guides for all the pages in the treating NHL section.
This page contains quite detailed information about the survival rates for different types and stages of non Hodgkin lymphoma. We have included it because many people have asked us for this. But not everyone who is diagnosed with a cancer wants to read this type of information. If you are not sure whether you want to know at the moment or not, then perhaps you might like to skip this page for now. You can always come back to it.
There is a section explaining more about the different types of cancer statistics in the section about incidence, mortality and survival. Unless you are very familiar with medical statistics, it might help to read this before you read the statistics below.
Remember that 5 year survival and 10 year survival are terms that doctors use. This doesn't mean that you will only live 5 or 10 years. The 10 year survival figure gives the number of people in research who are still alive 10 years after their diagnosis. Doctors follow what happens to people for 5 or 10 years after treatment in any research study. They do not like to say these people are cured because of the chance that the cancer will come back. With low grade lymphoma some people will still have the disease after 5 or 10 years but it can be kept under control with treatment. So, doctors usually talk about 5 year and 10 year survival instead of cure.
Please note that there are no national statistics available for different stages of lymphoma, or for treatments that people may have had. The statistics we present here are pulled together from a variety of different sources, including the opinions and experience of the experts that check each section of Cancer Research UK's patient information. We give statistics because people ask us for them. But they are only intended as a general guide and cannot be regarded as any more than that.
Of all those with non Hodgkin lymphoma, about 80 out of every 100 people (80%) will survive for a year or more after they are diagnosed. Around 70 out of every 100 people (70%) will survive for 5 years or more. And almost 65 out of every 100 people (65%) will survive for 10 years or more after they are diagnosed.
The outcome of non Hodgkin lymphoma depends on the type of lymphoma and in particular whether your lymphoma is low grade (indolent) or high grade (aggressive). But as with many other types of cancer, the outcome also depends on how advanced it is when it is diagnosed. In other words, the stage of your cancer.
Here we give information about the outlook for
We have survival statistics for each stage of these types of lymphoma, based on people in one area of England.
The most common type of low grade (indolent) lymphoma is follicular lymphoma. About 30 out of every 100 of all non Hodgkin lymphomas diagnosed (30%) are this type. Low grade lymphomas can be difficult to clear completely. But they are often kept under control for several years.
If your follicular lymphoma is diagnosed at an early stage, when it is localised, you may be cured with radiotherapy. Around 90 out of every 100 people diagnosed with stage 1 follicular lymphoma (90%) will survive for 5 years or more after they are diagnosed. And almost 90 out of 100 people with stage 2 follicular lymphoma (90%) will survive for 5 years or more. Almost 80 out of 100 people with stage 3 and stage 4 follicular lymphoma (80%) will survive for 5 years or more after they are diagnosed.
There is a scale that doctors use to help them to tell in advance who may be helped by particular types of chemotherapy. It is called the Follicular Lymphoma International Prognostic Index (FLIPI). It has identified 5 factors that doctors can use to try and tell who will do well after treatment. These 5 factors are
- Being older than 60 years
- Having stage 3 or 4 follicular lymphoma
- Having a low haemoglobin level
- Having more than 4 areas of lymph nodes affected with lymphoma
- A higher than normal blood level of an enzyme called LDH (serum lactate dehydrogenase)
The doctor looks at your situation to see whether you have any of these factors. If you do not have any poor prognostic factors you have a score of 0. People with all of the poor prognostic factors have a score of 5. The doctor can use this score to divide people with follicular lymphoma into 3 groups
- Low risk, if you have no or 1 poor prognostic factor
- Intermediate (moderate) risk, if you have 2 poor prognostic factors
- High risk, if you have 3 or more poor prognostic factors
A large French clinical trial looked at the 5 and 10 year survival for these 3 risk groups.
For the low risk group, around 90 out of every 100 people (90%) survive for 5 years or more after they are diagnosed. And around 70 out of every 100 people (70%) survive for 10 years or more.
For the intermediate risk group, almost 80 out of every 100 people (80%) survive for 5 years or more after diagnosis. And around 50 out of every 100 (50%) survive for 10 years or more.
For the high risk group, more than 50 out of every 100 people (50%) survive for 5 years or more after they are diagnosed. And more than 33 out of every 100 (33%) survive for 10 years or more.
It is important to remember that these numbers are averages. This means that they are only a guide and can't tell you what will happen to you. Your doctor can tell you more about your prognostic group, and how this might affect your outlook. You can read more about the stages of non Hodgkin lymphoma on this page.
Marginal zone lymphomas are a group of slow growing B cell lymphomas. About 12 out of every 100 B cell non Hodgkin lymphomas diagnosed (12%) are this type. Around 80 out of 100 people with stage 1 marginal zone lymphoma (80%) will survive for 5 years or more after diagnosis. And 75 out of 100 people with stage 2 (75%) will survive for 5 years or more.
Unfortunately the outlook isn't as good for stage 3 and stage 4. More than 50 out of 100 people with stage 3 marginal zone lymphomas (50%) will survive for 5 years or more after they are diagnosed. The outlook is slightly better for stage 4, and around 66 out of 100 people with stage 4 marginal zone lymphomas (66%) will survive for 5 years of more after their diagnosis.
There are different type of marginal zone lymphomas. These are
- Extranodal marginal zone B-cell lymphoma (also known as mucosa-associated lymphoid tissue (MALT) lymphoma)
- Nodal marginal zone B-cell lymphoma
- Splenic marginal zone B-cell lymphoma
Extranodal marginal zone B-cell lymphomas have a slightly better outcome than the other types. Almost 90 out of 100 people with this type of marginal zone lymphoma (90%) will survive for 5 years or more after they are diagnosed.
High grade (aggressive) lymphomas generally need more intensive treatment than the low grade types. But they often respond well to treatment. Many people are cured. The most common type of high grade lymphoma is diffuse large B cell lymphoma. About 31 in 100 of all lymphomas diagnosed (31%) are this type.
We have survival statistics for each stage of diffuse large B cell lymphoma, based on people in one area of England. The statistics are likely to be similar in the rest of the UK.
Almost 66 out of 100 people with stage1 diffuse large B cell lymphoma (66%) will survive for 5 years or more after they are diagnosed. And around 70 out of 100 people with stage 2 diffuse large B cell lymphoma (70%) will survive for 5 years or more.
Unfortunately the outlook for stage 3 and 4 diffuse large B cell lymphoma is less good. Over 50 out of 100 people with stage 3 (50%) will survive for 5 years or more. And almost 50 out of 100 people with stage 4 (50%) will survive for 5 years or more after their diagnosis.
Burkitt's lymphoma is another type of high grade lymphoma which can grow quite quickly. They make up about 3 out of 100 cases of lymphoma in the UK (3%). We don't have statistics for the different stages of Burkitt's lymphoma. But overall, almost 60 out of 100 people with Burkitt's lymphoma will survive for 5 years or more after they are diagnosed.
Whether you are likely to be cured depends on a number of different factors. Doctors identified these factors and grouped them together to make a prognostic index for people with diffuse large B cell lymphoma (a high grade lymphoma). A prognostic index is a way of trying to decide who has a greater risk of their lymphoma coming back after treatment. If high grade NHL comes back (relapses), it is less likely to be curable.
Age is one of the most important factors that affects outcomes. As you will see, you will need to talk this over with your doctor to get all the facts you need. This prognostic index was created before doctors used rituximab to treat lymphoma. Rituximab may lower the risk of lymphoma coming back. So this may affect the prognostic index in the future.
To work out the prognostic index, you score one point for each of the following:
- Aged over 60
- Stage 3 or 4 lymphoma at diagnosis
- Raised lactate dehydrogenase levels in your blood
- Performance status of more than 2 (see below)
- NHL in more than one site outside your lymphatic system (extranodal disease), for example, in your bones
Performance status is a scoring system that describes how well you are and how much you can look after yourself. 0 means you are fully active and well. If you need to stay in bed or a chair for more than half the day and need a lot of help to look after yourself, your performance status will be more than 2.
If your score from the prognostic index is 0 or 1, then you are more likely to respond well to treatment, and your lymphoma is unlikely to come back. If you scored 2, then you are at moderately low risk of your lymphoma coming back.
A score of 3 means you have a moderately high risk of the lymphoma coming back. If you scored 4 or 5, then unfortunately you are at a higher than average risk of not responding to treatment, or of having your lymphoma come back after treatment.
Remember that scoring systems can only ever provide a guess based on what has happened to patients in the past. In other words, you can score highly and still respond well to treatment. It can only be used as a guide. And this scale is only for people with diffuse large B cell lymphomas not low grade lymphomas.
No statistics can tell you what will happen to you. Your cancer is unique. The same type of cancer can develop at different rates in different people.
The statistics are not detailed enough to tell you about the different treatments people may have had. And how that treatment may have affected their prognosis. Some treatments may help people to live longer as well as relieving symptoms. There are many individual factors that will affect your treatment and prognosis.
Clinical trials have made a great difference to the treatment and prognosis of both low grade and high grade lymphomas. Trials of combination chemotherapy have improved response rates for high grade lymphomas. Now, trials are investigating combining these standard treatments with newer treatments such as biological therapies. New treatments such as monoclonal antibody therapy (a type of biological therapy) are increasing the survival time for low grade lymphomas.
If you are interested in taking part in a clinical trial for lymphoma, go to our clinical trials database. If you would like to know more about clinical trials, look at our about clinical trials section.
Rated 4 out of 5 based on 199 votes
Question about cancer? Contact our information nurse team